Short Title:
CIPHER Coronary Responses- ISS
Responsible HRP Element:
Human Health Countermeasures
Funding Status:
Active - Currently funded and in progress
|
Procurement Mechanism(s):
|
|
Aims:
Specific Aim 1: To test the hypothesis that coronary atherosclerosis will be accelerated by 1 year of spaceflight. We will perform coronary CT angiography (cCTA): a) 1 year before flight upon crew selection; b) within 4-8 weeks of flight; c) soon (within 1-2 weeks) after 1 year in space; and d) after 1 year recovery. This strategy will allow us to compare the trajectory of coronary atherosclerosis before and after prolonged spaceflight. The extent of calcified and non-calcified plaque will be quantified, and markers of plaque vulnerability will be assessed. To provide context, we will also compare these data to well matched controls from the Cooper Clinic Longitudinal Study and the PARADIGM cCTA registry.
Specific Aim 2: To test the hypothesis that 1 year in space will impair coronary endothelial function and vasomotor reactivity. We will perform myocardial contrast echocardiography (MCE) before and after adenosine pre, in, and post-flight to quantify coronary microvascular function.
Exploratory Aim 3: To test the hypothesis that a multimodality biomarker panel including blood (hs-troponin, NT-proBNP, markers of oxidative stress and DNA damage) and relevant imaging (CAC, cCTA, MCE) can quantify risk of accelerated atherosclerosis before and during long duration flight.
Category:
Risk Characterization, Quantification
Subcategory:
Evidence or Risk Characterization
Description:
(1) Characterization of coronary atherosclerotic changes due to spaceflight.
(2) Characterization of coronary endothelial function and vasomotor reactivity due to spaceflight.
Internal Customers:
None
External Customers:
None